clinical trial · NCT06757335
A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
Breast CancerHP568HP568 in combination with palbociclib
brief summary
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or metastatic breast cancer.
started
Jan 7, 2025
primary completion
Jan 31, 2026
completion
Nov 27, 2026
last updated
Jan 3, 2025
official title
A Multicenter, Open, Dose Escalation/dose Escalation, and Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral HP568 Tablets Alone and in Combination with Palbociclib in Patients with ER+/HER2 Advanced Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol